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Abstract
Background: Apolipoprotein A1 (ApoA1) is the major apoprotein constituent of high-density lipoprotein that can
play important roles in tumor invasion and metastasis. The objective of the present study was to evaluate the association
of two genetic variants (−75 G/A and +83 C/T) of APOA1 with predisposition to renal cancer.
Methods: A total of 432 subjects, including 216 pathologically-proven renal cancer cases and 216 age- and
gender-matched healthy controls, were recruited into this hospital-based case–control study. Genotyping of the APOA1
was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) combined with gel
electrophoresis, and then confirmed by direct sequencing.
Results: Patients with renal cancer had a significantly higher frequency of APOA1 -75 AA genotype [odds ratio (OR) = 2.10,
95 % confidence interval (CI) = 1.18, 3.75; P = 0.01] and APOA1 -75 A allele (OR =1.40, 95 % CI = 1.05, 1.87; P = 0.02) than
controls. When stratifying by the distant metastasis status, patients with distant metastasis had a significantly
higher frequency of APOA1 -75 AA genotype genotype (OR =2.20, 95 % CI = 1.04, 4.68; P = 0.04).
Conclusion: This study is, to our knowledge, the first to examine prospectively an increased risk role of APOA1 -75 AA
genotype and APOA1 -75 A allele in renal cancer susceptibility.
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Introduction
Renal cancer is the predominant form of malignancy of
the kidney and represents 3–4 % of all cancers [1]. In
2015, an estimated 61,560 new cases of kidney and renal
pelvis cancers will be diagnosed in the United States [1].
An estimated 14,080 Americans are expected to die from
the disease in 2015 [1]. The crude incidence rates of
renal cell carcinoma were 7.1 and 3.1 per 100,000 popu-
lation for men and women respectively in Japan in 1997
[2]. The crude incidence rates of renal cell carcinoma
were increased from 4.5 to 5.6 per 100,000 population in
China between 1989 and 2008 [3, 4]. Many epidemio-
logical studies have found that environmental factors,
such as smoking, diesel exhaust, and various dioxins,
may be involved in the development of sporadic renal
cancer [5–8]. Although many subjects are exposed to
these risk factors during their lifetime, only some of
them develop renal cancer, which suggests that genetic
susceptibility may play a role in the etiology of renal
cancer [9]. The impact of genetic background on renal
cancer is still unclear.
Apolipoprotein A1 (ApoA1) is the major apoprotein
constituent of high-density lipoprotein (HDL) that can
play important roles in tumor invasion and metastasis
[10, 11]. Recent findings revealed the crucial roles of
ApoA1 in inflammation, tumor growth, angiogenesis,
invasion and metastasis [12–14]. APOA1 gene, located
on the 11q23-q24, encodes apoA1 [11, 15]. There are
several single-nucleotide polymorphisms (SNPs) in the
APOA1 gene [16]. Two SNPs (−75 G/A and +83 C/T)
of APOA1 play an important role in lipid metabolism
[17–19]. It has also been found that APOA1 -75 G/A
and +83 C/T genotypes were associated with susceptibility
to breast cancer and lymph node metastases occurrence,
respectively [20].
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To our best knowledge, no reports concerning the role
of APOA1 -75 G/A and +83 C/T genotypes on renal can-
cer risk have been reported yet. We hypothesized that
APOA1 -75 G/A and +83 C/T genotypes were associated
with renal cancer risk. To test this hypothesis, we per-
formed a prospective hospital-based case–control study to
evaluate the association of the APOA1 -75 G/A and +83
C/T genotypes with predisposition to renal cancer.
Materials and methods
Study population
A total of 432 subjects, including 216 pathologically-proven
renal cancer cases and 216 age- and gender-matched
healthy controls, were recruited into this hospital-based
case–control study between February 2012 and December
2014 in the West China Hospital of Sichuan University
[21]. All renal cancer cases were histopathologically con-
firmed. We extracted the following information: tumor
grade, tumor classification, lymph node invasion status, dis-
tant metastasis status and the pathology of renal cancer. In
order to confirm that healthy controls were healthy and
free of cancer, volunteers underwent various tests that
included physical exams, questionnaires about their health
and history, chest X-rays, blood and urine tests for various
tumor markers, abdominal ultrasound, gastric endoscopy,
and colon enema. The patient or their families/surrogates
were interviewed. The Institutional Ethical Committee of
the West China Hospital of Sichuan University approved
all parts of the study, and informed consent according to
the Declaration of Helsinki was obtained from all partici-
pants or their families/surrogates.
DNA extraction and genotyping
Genomic DNA was isolated from 20 g/L ethylenediamine-
tetraacetic acid (EDTA) or sodium citrate anticoagulated
3–5 ml venous blood by the commercially available
Qiagen kit (QIAGEN Inc., Valencia, CA, USA) and stored
at 4 °C. Genotyping of the APOA1 was performed by poly-
merase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP). Based on the GenBank reference
sequence, the PCR primers designed for the APOA1 -75 G/
A and +83 C/T were as follows: 5 -AGG GAC AGA
GCT GAT CCT TGA ACT CTT AAG-3 (forward) and
5 -TTA GGG GAC ACC TAG CCC TCA GGA AGA
GCA-3 (reverse). The restriction endonuclease enzyme
MspI digested the amplified PCR products overnight. Elec-
trophoresis in a 3 % agarose gel followed by ethidium
bromide staining and ultraviolet illumination allowed detec-
tion of the alleles. The presence of the MspI restriction stie
at −75 bp (G allele) and at +83 bp (C allele) in the 433 bp
product resulted in four fragments of 45, 66, 113 and
209 bp (Fig. 1). The absence of the restriction site at −75 bp
(A allele) resulted in three fragments of 45, 179 and 209 bp
(Fig. 1). The absence of the restriction site at +83 bp (T
allele) created a larger fragment of 254 bp instead of two
fragments of 45 and 209 bp (Fig. 1). For quality control,
two independent observers randomly chose 44 samples (22
cases and 22 controls) by computer-generated number
scheme. They performed double sampling PCR-RFLP and
found no differences, and then confirmed by direct sequen-
cing from Qiagen cleaned up DNA.
Statistical analysis
Data are presented as percentages for categorical variables
or as means ± standard deviation (SD). Differences between
categorical variables were evaluated using Pearson x2 test,
while those between continuous variables were assessed by
Student’s t test. The existence of differences in genotypic
frequencies between groups was assessed by means of
Pearson x2 test and calculating the odds ratio (OR) with
the 95 % confidence intervals (CI). A P-value was consid-
ered significant at a level of < 0.05. The Statistical Analysis
Fig. 1 Electrophoresis in a 3 % agarose gel after the Mspl digested in renal cancer cases and healthy controls
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System software (Version 9.1; SAS Institute Inc., Cary, NC,
USA) was used for all statistical tests.
Results
Characteristics of participants
Healthy volunteers and cancer patients were not signifi-
cantly different in terms of age distribution and gender
(Table 1). For renal cancer cases, the tumor grade, tumor
classification, lymph node invasion status, distant metasta-
sis status and pathology were presented in a separate
paper [21].
APOA1 -75 G/A polymorphisms and renal cancer
Patients with renal cancer had a significantly higher fre-
quency of APOA1 -75 AA genotype [odds ratio (OR) =
2.10, 95 % confidence interval (CI) = 1.18, 3.75; P = 0.01]
and APOA1 -75 A allele (OR =1.40, 95 % CI = 1.05, 1.87;
P = 0.02) than controls (Table 2). When stratifying by
the distant metastasis status, patients with distant metas-
tasis had a significantly higher frequency of APOA1 -75
AA genotype genotype (OR =2.20, 95 % CI = 1.04, 4.68;
P = 0.04) (Table 3). When stratifying by the tumor grade,
tumor classification, lymph node invasion status and path-
ology, no significant differences were found (Table 3).
APOA1 + 83 C/T polymorphisms and renal cancer
We did not find any association between APOA1 + 83 C/T
polymorphisms and renal cancer risk (Table 2).
Discussion
Many studies have suggested that genetic susceptibility
may play a role in the etiology of renal cancer. The
DKK3 polymorphisms were associated with renal cancer
and that the DKK2 rs17037102 polymorphism might be
a predictor for survival in patients with renal cancer
after radical nephrectomy [22]. We recently found that
IL-6 -174 CC genotype was associated with an increased
risk for renal cancer [21]. The functional -31G/C poly-
morphism in the promoter of survivin might influence
the susceptibility and progression of renal cancer in the
Chinese population [23]. The polymorphisms of the
CYP1B1 gene at codons 119 and 432 might be risk fac-
tors for renal cancer, especially in the male population
[7]. The CYP1A1 polymorphisms might play an important
role in the etiology of renal cancer [24]. The polymor-
phisms of catechol-O-methyltransferase in men were asso-
ciated with renal cancer [25]. The R allele of paraoxonase-1
gene Q192R polymorphism might protect against renal
cancer [26]. Two SNPs in AGTR1 might be a candidate
pathway in renal cancer etiology [27]. Polymorphisms in
genes of the renin-angiotensin-aldosterone system (AGTR1
and AGT) influenced renal cell cancer susceptibility [27]. A
common variant, rs35252396, at 8q24.21 was associated
with renal cell cancer [28].
The APOA1 gene polymorphisms were also associated
with many other diseases. It has been found that the
APOA1 -75 G/A polymorphism was associated with gall-
stone disease [29]. The APOA1 -75 G/A and +83 C/T geno-
types were also associated with susceptibility to breast
Table 1 General characteristics of renal cancer cases and
healthy controls
Variables Cases Controls P
Number of subjects 216 216
Gender (Men/Women) 165/135 163/137 0.87

















Clear cell carcinoma 197
Granular cell carcinoma 15
Chromophobe cell carcinoma 4
Abbreviations: SD, standard deviation
Table 2 Genotype and allele frequencies of APOA1 gene
polymorphisms (−75 G/A and +83 C/T) among renal cancer
cases and healthy controls
Genotypes Cases (%) Controls (%) OR (95 %CI) P
− 75 GG 108 (50.0) 119 (55.1) 1.00 (Reference)
− 75 GA 66 (30.6) 75 (34.7) 0.97 (0.64,1.48) 0.89
− 75 AA 42 (19.4) 22 (10.2) 2.10 (1.18,3.75) 0.01
−75 G allele frequency 282 (65.3) 313 (72.5) 1.00 (Reference)
−75 A allele frequency 150 (34.7) 119 (27.5) 1.40 (1.05,1.87) 0.02
+ 83 CC 145 (67.1) 136 (63.0) 1.00 (Reference)
+ 83 CT 45 (20.8) 49 (22.7) 0.86 (0.54,1.38) 0.53
+ 83 TT 26 (12.1) 31 (14.3) 0.79 (0.44,1.39) 0.41
+83 C allele frequency 335 (77.5) 321 (74.3) 1.00 (Reference)
+83 T allele frequency 97 (22.5) 111 (25.7) 0.84 (0.61,1.15) 0.27
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cancer and lymph node metastases occurrence, respectively
[20]. A pilot study found that APOA1 polymorphisms
(−75 G/A and +83 C/T) might be susceptibility to myocar-
dial infarction in a north Indian population [19]. The indi-
viduals with the APOA1 -75 A allele were likely to have a
lower risk of coronary artery disease as a result of its effect
on higher serum concentrations of ApoA1 and HDL-C
[30]. The APOA1 -75G/A promoter polymorphism was
associated with cognitive performance in multiple sclerosis
[31]. It has been found that the APOA1 polymorphisms
(−75 G/A and +83 C/T) could be as risk factors for hyper-
tension and obesity in a Brazilian elderly cohort [32]. The
APOA1 -75 A allele was associated with an increased risk
for Alzheimer’s disease [33]. The APOA1 -75 AA genotype
was associated with a higher acute lung injury risk after
cardiopulmonary bypass surgery [34].
The exact biological mechanism of the association
between the APOA1 -75G/A polymorphisms and the risk
of renal cancer is still unclear. ApoA1 can play important
roles in tumor growth, angiogenesis, invasion and metasta-
sis [12–14]. Expression of ApoA1 is associated with
colonic adenocarcinoma progression, and thus ApoA1 is a
potential marker of the aggression [35]. It has also been
found that APOA1 -75 G/A and +83 C/T genotypes were
associated with susceptibility to breast cancer and lymph
node metastases occurrence, respectively [20]. A recent
fascinating study reveals an overall protective ability of
HDL, specifically APOA1, to induce tumor suppression
through both innate and adaptive immune processes in
multiple animal tumor models [36]. Tabet et al. demon-
strated that HDL’s anti-inflammatory properties were con-
ferred, in part, through HDL-micro-RNA (miR)-223
delivery and translational repression of ICAM-1 in endo-
thelial cells [37]. However, the miR221/222 cluster
increases the aggressiveness of tumors in epithelial cancers,
through repression of tumor suppressors and through
induction of cell motility [38]. APOA1 allelic variety may
have an impact on angiogenesis [39]. APOA1 binding pro-
tein (AIBP) positively regulates cholesterol efflux from
endothelial cells and that effective cholesterol efflux is crit-
ical for proper angiogenesis [39]. AIBP is highly expressed
in human renal cancer and in 83 % of cancers in general
[39]. But there is no study about the interaction of AIBP
and the APOA1 alleles. Further research on the possible
interaction of AIBP and the APOA1 alleles is necessary.
Some shortcomings of this study should be mentioned.
First of all, potential selection bias might have been
present, because this is a hospital based case control
study and the subjects may not be representative of the
general population. Second, this study is limited by its
size and lack of replication. Finally, further research on
the biological mechanism of the association between the
APOA1 -75G/A polymorphisms and the risk of renal
cancer is necessary.
Table 3 Stratification analysis of APOA1 -75 G/A polymorphisms in renal cancer cases
Cases GG GA AA
n (%) OR (95 %CI) P n (%) OR (95 %CI) P n (%) OR (95 %CI) P
Grade 216 108 (50.0) 1 (Reference) 66 (30.6) 1 (Reference) 42 (19.4) 1 (Reference)
1 55 28 (50.9) 1.02 (0.61,1.70) 0.95 15 (27.3) 0.89 (0.47,1.68) 0.73 12 (21.8) 1.12 (0.55,2.27) 0.75
2 129 64 (49.6) 0.99 (0.68,1.45) 0.97 42 (32.6) 1.07 (0.68,1.66) 0.78 23 (17.8) 0.92 (0.53,1.59) 0.76
3 + 4 32 16 (50.0) 1.00 (0.53,1.90) 1.00 9 (28.1) 0.92 (0.42,2.03) 0.84 7 (21.9) 1.13 (0.47,2.72) 0.79
Tumor classification 216 108 (50.0) 1 (Reference) 66 (30.6) 1 (Reference) 42 (19.4) 1 (Reference)
T1 103 55 (53.4) 1.07 (0.72,1.59) 0.75 29 (28.2) 0.92 (0.56,1.51) 0.75 19 (18.4) 0.95 (0.53,1.71) 0.86
T2 49 22 (44.9) 0.90 (0.52,1.56) 0.70 16 (32.7) 1.07 (0.57,2.00) 0.84 11 (22.4) 1.16 (0.56,2.40) 0.70
T3 57 28 (49.1) 0.98 (0.59,1.63) 0.95 19 (33.3) 1.09 (0.61,1.96) 0.77 10 (17.6) 0.90 (0.43,1.91) 0.79
T4 7 3 (42.8) 0.86 (0.22,3.38) 0.83 2 (28.6) 0.94 (0.19,4.61) 0.93 2 (28.6) 1.47 (0.29,7.32) 0.64
Lymph node invasion status 216 108 (50.0) 1 (Reference) 66 (30.6) 1 (Reference) 42 (19.4) 1 (Reference)
Negative 199 99 (49.7) 0.99 (0.71,1.39) 0.98 61 (30.7) 1.00 (0.67,1.49) 0.99 39 (19.6) 1.01 (0.63,1.62) 0.97
Positive 17 9 (52.9) 1.06 (0.46,2.45) 0.89 5 (29.4) 0.96 (0.34,2.71) 0.94 3 (17.7) 0.91 (0.26,3.24) 0.88
Distant metastasis status 216 108 (50.0) 1 (Reference) 66 (30.6) 1 (Reference) 42 (19.4) 1 (Reference)
Negative 188 99 (52.7) 1.05 (0.75,1.47) 0.76 59 (31.4) 1.03 (0.69,1.54) 0.90 30 (15.9) 0.82 (0.49,1.36) 0.45
Positive 28 9 (32.1) 0.64 (0.29,1.41) 0.27 7 (25.0) 0.82 (0.34,1.96) 0.65 12 (42.9) 2.20 (1.04,4.68) 0.04
Pathology 216 108 (50.0) 1 (Reference) 66 (30.6) 1 (Reference) 42 (19.4) 1 (Reference)
Clear cell carcinoma 197 99 (50.2) 1.01 (0.72,1.40) 0.98 60 (30.5) 1.00 (0.67,1.49) 0.99 38 (19.3) 0.99 (0.61,1.60) 0.97
Granular cell carcinoma 15 7 (46.7) 0.93 (0.37,2.36) 0.88 5 (33.3) 1.09 (0.38,3.11) 0.87 3 (20.0) 1.03 (0.29,3.71) 0.97
Chromophobe cell carcinoma 4 2 (50.0) 1.00 (0.18,5.55) 1.00 1 (25.0) 0.82 (0.09,7.45) 0.86 1 (25.0) 1.29 (0.14,11.79) 0.82
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In conclusion, to our best knowledge, up to now this
study is the first to examine prospectively an increased
risk role of APOA1 -75 AA genotype and APOA1 -75 A
allele in renal cancer susceptibility.
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